Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig H Moskowitz

Showing results (41-50 of 143) with videos related to

Pageof 15
Sort By:
Blood Advances|June 20, 2020
KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failurePhilippe Armand, John Kuruvilla, Jean-Marie Michot, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 19, 2014
Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantationCraig S Sauter, Lauren Lechner, Michael Scordo, et al.
International Journal of Radiation Oncology, Biology, Physics|March 24, 2017
Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of ExperienceAndreas Rimner, Shona Lovie, Meier Hsu, et al.
Leukemia & Lymphoma|July 16, 2005
R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacyJeffrey L Halaas, Craig H Moskowitz, Steven Horwitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicityBradford S Hoppe, Craig H Moskowitz, Daniel A Filippa, et al.
Cancer Journal (Sudbury, Mass.)|November 6, 2002
Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantationDorothy Pan, Craig H Moskowitz, Andrew D Zelenetz, et al.
British Journal of Haematology|December 17, 2016
Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab eraSantosha A Vardhana, Craig S Sauter, Matthew J Matasar, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2018
Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to TransplantSantosha Vardhana, Paul A Hamlin, Joanna Yang, et al.
Radiology|June 3, 2015
Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive LymphomaGary A Ulaner, Debra A Goldman, Craig S Sauter, et al.
British Journal of Haematology|May 15, 2009
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphomaAlison J Moskowitz, Miguel-Angel Perales, Tarun Kewalramani, et al.
Pageof 15

Showing results (41-50 of 143) with videos related to

Sort By:
Pageof 15
Blood Advances|June 20, 2020
KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failurePhilippe Armand, John Kuruvilla, Jean-Marie Michot, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 19, 2014
Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantationCraig S Sauter, Lauren Lechner, Michael Scordo, et al.
International Journal of Radiation Oncology, Biology, Physics|March 24, 2017
Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of ExperienceAndreas Rimner, Shona Lovie, Meier Hsu, et al.
Leukemia & Lymphoma|July 16, 2005
R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacyJeffrey L Halaas, Craig H Moskowitz, Steven Horwitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicityBradford S Hoppe, Craig H Moskowitz, Daniel A Filippa, et al.
Cancer Journal (Sudbury, Mass.)|November 6, 2002
Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantationDorothy Pan, Craig H Moskowitz, Andrew D Zelenetz, et al.
British Journal of Haematology|December 17, 2016
Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab eraSantosha A Vardhana, Craig S Sauter, Matthew J Matasar, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2018
Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to TransplantSantosha Vardhana, Paul A Hamlin, Joanna Yang, et al.
Radiology|June 3, 2015
Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive LymphomaGary A Ulaner, Debra A Goldman, Craig S Sauter, et al.
British Journal of Haematology|May 15, 2009
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphomaAlison J Moskowitz, Miguel-Angel Perales, Tarun Kewalramani, et al.
Pageof 15